NCT05173792View on ClinicalTrials.gov

Study of AK119 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

May 22, 2023

Study Completion Date

May 22, 2023

Conditions

Solid Tumor

Interventions

DRUG

AK119

Subjects will receive AK119 intravenously.

Trial Locations (2)

200032

Fudan University Zhongshan Hospital, Shanghai

300060

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT05173792 - Study of AK119 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter